References
- Aoki S, Matsumoto K, Ohta K, et al. (2006). An emulsion of sulfoquinovosylacylglycerol and long-chain alkane increases its permeability in tumor cells. J Membrane Biol 213:11–8.
- Aoki S, Ohta K, Yamazaki T, et al. (2005). Mammalian mitotic centromere-associated kinesin (MCAK), a new molecular target of sulfoquinovosylacylglycerols (SQAGs), novel anti-tumor and immunosuppressive agents. FEBS J 272:2132–40.
- Hanashima S, Mizushina Y, Ohta K, et al. (2000a). Structure-activity relationship of a novel inhibitor group of mammalian DNA polymerases, synthetic sulfoquinovosylacylglycerols. Jpn J Cancer Res 91:73–83.
- Hanashima S, Mizushina Y, Yamazaki T, et al. (2000b). Structural determination of sulfoquinovosyldiacylglycerol by chiral synthesis. Tetrahedron Lett 41:4403–7.
- Hanashima S, Mizushina Y, Yamazaki T, et al. (2001). Synthesis of sulfoquinovosylacylglycerols, inhibitors of eukaryotic DNA polymerase α and β. Bioorg Med Chem 9:367–76.
- Herman TS, Teicher BA, Dewhirst MW, Zimmerman D. (1990). Rate of infusion: an important factor in circulatory effects of perfluorochemical emulsions (PFCES). Int J Radiat Oncol Biol Phys 19:136.
- Iwamoto H, Nakamura T, Koga H, et al. (2015). Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces “angiogenic switch off” in a hepatoma mouse model. Mol Ther Oncolytics 2:15020.
- Izaguirre-Carbonell J, Kawakubo H, Murata H, et al. (2015). Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulate its activity. Nat Commun 5:15136.
- Izaguirre-Carbonell J, Murata H, Ohta K, et al. (2014). Identification and study of SQAP-binding proteins from a T7 phage display screen. Planta Med 80:PH4.
- Miura M, Sakimoto I, Ohta K, et al. (2007). Sulfoglycolipids as candidate antiangiogenetic radiosensitizers: a review. Anticancer Drugs 18:1–5.
- Ohta K, Mizushina Y, Yamazaki T, et al. (2001). Specific interaction between oligosaccharide on tumor cell surface and novel antitumor agents, sulfoquinovosylmonoacylglycerols. Biochem Biophys Res Commun 288:893–900.
- Ohta K, Murata H, Mori Y, et al. (2010). Remodeling of the tumor microenvironment by combined treatment with a novel radiosensitizer, α-sulfoquinovosylmonoacylglycerol (α-SQMG) and X-irradiation. Anticancer Res 30:4397–404.
- Sakaguchi K. (2015). A prospect of a new potent radiosensitizer SQAG/SQAP (a review in Japanese). Radiat Biol Res Commun 50:1–17.
- Sakaguchi K, Sugawara F. (2008). New cancer chemotherapy agents: Inhibitors of DNA polymerase: a review. Curr Drug Ther 3:44–53.
- Sakimoto I, Ohta K, Yamazaki T, et al. (2006). α-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 66:2287–95.
- Sawada Y, Omoto K, Kohei H, et al. (2015). Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer. Int J Urol 22:590–5.
- Takakusagi Y, Matsumoto S, Saito K, et al. (2015). Increase in tumor oxygenation and radiosensitivity caused by SQAP (CG-0321): the mechanism of actions revealed by in vivo imaging studies. ICRR (15th International Congress of Radiation Research) 3-PS2E-27.
- Takakusagi Y, Takakusagi K, Ida N, et al. (2011). Binding region and interaction properties of sulfoquinovosylacylglycerol (SQAG) with human vascular endothelial growth factor 165 revealed by biosensor-based assays. Med Chem Commun 2:1188–93.
- Takakusagi Y, Takakusagi K, Sugawara F, Sakaguchi K. (2010). Use of phage display technology for the determination of the targets for small-molecule therapeutics (a review). Expert Opin Drug Discov 5:361–89.
- Yuan H, Schroeder T, Bowsher JE, et al. (2006). Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 47:989–98.